Literature DB >> 28944534

Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.

Yutaka Kuwatsuka1, Akira Iwanaga1, Sayaka Kuwatsuka1, Yumi Okubo1,2, Naoya Murayama1, Norito Ishii3, Takashi Hashimoto4, Atsushi Utani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28944534     DOI： 10.1111/1346-8138.14043

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  10 in total

1.  Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Authors:  Coralie Zumelzu; Marina Alexandre; Christelle Le Roux; Patricia Weber; Alexis Guyot; Annie Levy; Françoise Aucouturier; Sabine Mignot-Grootenboer; Frédéric Caux; Eve Maubec; Catherine Prost-Squarcioni
Journal:  Front Med (Lausanne)       Date:  2018-09-27

Review 2.  Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma.

Authors:  Irene Russo; Ludovica Zorzetto; Vanna Chiarion Sileni; Mauro Alaibac
Journal:  Scientifica (Cairo)       Date:  2018-12-30

Review 3.  Management of immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Xiaoyan Si; Chunxia He; Li Zhang; Xiaowei Liu; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Mengzhao Wang; Li Zhang
Journal:  Thorac Cancer       Date:  2019-12-09       Impact factor: 3.500

4.  Immune checkpoint inhibitors-induced eosinophilic pneumonia: A case report.

Authors:  Kanako Hara; Kei Yamasaki; Masahiro Tahara; Rieko Kimuro; Yudai Yamaguchi; Yu Suzuki; Hiroki Kawabata; Toshinori Kawanami; Naohiro Fujimoto; Kazuhiro Yatera
Journal:  Thorac Cancer       Date:  2021-01-21       Impact factor: 3.500

5.  A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

Authors:  Xiaoxiao Wang; Mariano Suppa; Pascal Bruderer; Nicolas Sirtaine; Sandrine Aspeslagh; Joseph Kerger
Journal:  Case Rep Oncol       Date:  2021-06-15

Review 6.  A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Authors:  Adriana T Lopez; Larisa Geskin
Journal:  Oncologist       Date:  2018-07-17

7.  Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma.

Authors:  T Hanley; S Papa; M Saha
Journal:  JRSM Open       Date:  2018-10-03

Review 8.  Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.

Authors:  Ian William Tattersall; Jonathan Scott Leventhal
Journal:  Yale J Biol Med       Date:  2020-03-27

9.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.